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Aims: Patients on antituberculosis (anti-TB) therapy are at risk of drug-induced liver
injury (DILI). MicroRNA-122 (miR-122) and cytokeratin-18 (K18) are DILI biomarkers.
To explore their utility in this global context, circulating miR-122 and K18 were mea-
sured in UK and Ugandan populations on anti-TB therapy for mycobacterial
infection.
Methods: Healthy subjects and patients receiving anti-TB therapy were recruited at
the Royal Infirmary of Edinburgh, UK (ALISTER—ClinicalTrials.gov Identifier:
NCT03211208). African patients with human immunodeficiency virus–TB coinfec-
tion were recruited at the Infectious Diseases Institute, Kampala, Uganda (SAEFRIF—
NCT03982277). Serial blood samples, demographic and clinical data were collected.
In ALISTER samples, MiR-122 was quantified using polymerase chain reaction. In
ALISTER and SAEFRIF samples, K18 was quantified by enzyme-linked immunosor-
bent assay.
Results: The study had 235 participants (healthy volunteers [n = 28]; ALISTER: active
TB [n = 30], latent TB [n = 88], nontuberculous mycobacterial infection [n = 25];
SAEFRIF: human immunodeficiency virus-TB coinfection [n = 64]). In the absence of
DILI, there was no difference in miR-122 and K18 across the groups. Both miR-122
and K18 correlated with alanine transaminase (ALT) activity (miR-122: R = .52, 95%
CI = 0.42–0.61, P < .0001. K18: R =0.42, 95%CI = 0.34–0.49, P < .0001). miR-122
distinguished those patients with ALT>50 U/L with higher sensitivity/specificity than
K18. There were 2 DILI cases: baseline ALT, 18 and 28 IU/L, peak ALT 431 and
194 IU/L; baseline K18, 58 and 219 U/L, peak K18 1247 and 3490 U/L; baseline
miR-122 4 and 17 fM, peak miR-122 60 and 336 fM, respectively.
Conclusion: In patients treated with anti-TB therapy, miR-122 and K18 correlated
with ALT and increased with DILI. Further work should determine their diagnostic
and prognostic utility in this global context-of-use.
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1 | INTRODUCTION
Tuberculosis (TB) is in the top 10 global causes of death, with an esti-
mated 10 million new cases, 1.2 million deaths among human immu-
nodeficiency virus (HIV)-negative individuals and 251 000 deaths
among HIV-positive individuals in 2018.1 The global burden of TB is
unequally distributed, disproportionately affecting low- and middle-
income countries particularly in Africa and Asia. One of the barriers to
the effective treatment of TB are the adverse drug reactions experi-
enced by patients on anti-TB medications, with 1 of the most com-
mon being drug-induced liver injury (DILI).2 Three of the 4 first-line
drugs used in the treatment of TB—isoniazid, rifampicin and
pyrazinamide—are potentially hepatotoxic.3 The estimate of the inci-
dence of DILI in individuals undergoing anti-TB treatment for active
TB varies from 2 to 33% depending on the cohort studied, drug regi-
men used, monitoring and reporting practices.2,4,5 Individuals who
experience DILI often need to stop treatment and, if clinically indi-
cated, recommence once liver function tests (LFTs) return to normal.
However, for some individuals, re-exposure to the same drugs leads
to reoccurrence of DILI,6 and for others, liver injury progresses even
after treatment has stopped.7 Therefore, there is an unmet clinical
need for new tools to improve the safety of this essential antimicro-
bial treatment.
Diagnosis of DILI relies on LFTs, with alanine aminotransferase
(ALT) activity considered a gold standard for determining liver injury.
The DILI Expert Working Group defines DILI as ≥3× upper limit of
normal (ULN) of ALT in the presence of symptoms, or ≥5× ULN ALT
in the absence of symptoms.8 Although ALT is currently the gold stan-
dard for determining DILI, there are issues associated with its use.
ALT is not specific to the liver and can provide false positive results,
with elevations in ALT occurring after muscular damage following
exercise9 or subsequent to a myocardial infarction.10 Furthermore,
elevations in ALT are not specific to DILI11 and can occur due to met-
abolic perturbations.12,13 In paracetamol-overdose DILI, there is a
delay between insult to the liver and rise in ALT,14 meaning ALT is not
optimal as a biomarker of DILI in this context. To address these chal-
lenges recent work has identified novel biomarkers capable of diag-
nosing, and in some cases predicting DILI.
MicroRNAs (miRNAs) are small noncoding RNAs regulate post-
transcriptional gene expression. MiR-122 is a 22-nucleotide micro-
RNA is highly expressed in, and highly specific for, the liver, with little
to no expression in other tissues. In liver injury, miR-122 is released
from necrotic hepatocytes, resulting in elevated miR-122 concentra-
tions in the bloodstream.15 Cytokeratin-18 (K18) is an intermediate
filament protein responsible for maintaining the cytoskeletal structure
in the liver and other epithelial cells and is reported to make up 5% of
the liver's total protein content.16 K18 is a mechanistic biomarker of
liver injury, providing information on the pattern of cell death. In
apoptosis, the release of a caspase-cleaved form of K18 (cc-K18) is an
early event during cellular structural rearrangement,17 whereas, in
necrosis, the full-length form of K18 (FL-K18) is passively released
upon cell death.17 MiR-122 and K18 are able to predict DILI in
patients who overdose on paracetamol earlier than standard LFTs18,19
and provides enhanced hepatic specificity over other biomarkers.20
Both novel biomarkers have regulatory support from the US Food and
Drug Administration as biomarkers for DILI,21 although to date their
development has been largely limited to testing in western
populations.
The aim of this study was to explore the properties of miR-122
and K18 in relevant European and African patients with mycobacterial
infection (with and without HIV coinfection). Specifically, our aims
were to determine whether the infective disease process and routine
What is already known about this subject
• Drug-induced liver injury (DILI) is a major concern in the
treatment of tuberculosis (TB).
• There are new biomarkers for DILI (microRNA-122 and
cytokeratin-18) that have the potential to add value
because of enhanced specificity/sensitivity compared to
current tests.
• These mechanistically informative DILI biomarkers have
qualifying data from large USA and European studies.
However, these markers have not been tested in Africa.
Given the global burden of TB our aim was to explore
biomarker utility in this global context of use.
What this study adds
• The baseline concentrations of cytokeratin-18 did not
substantially differ across UK and Ugandan populations
on treatment for TB and human immunodeficiency virus.
MicroRNA-122 did not differ across healthy subjects and
UK patients treated for mycobacterial infection.
• These biomarkers significantly correlated with alanine
transaminase activity (current liver injury marker) and
were elevated with DILI. MicroRNA-122 distinguished
those patients with alanine transaminase >50 U/L with
higher sensitivity/specificity than K18.
• MicroRNA-122 and cytokeratin-18 have potential in this
context-of-use and should be taken forward into larger
studies, which could provide data for formal qualification.
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management with anti-TB medicines affect these biomarkers in the
absence of DILI and to characterise how miR-122 and K18 change in
relation to ALT and in cases of DILI.
2 | METHODS
Participants with active TB, latent TB and nontuberculous mycobacte-
rial (NTM) infection were recruited into the Assessing Antibiotic-
Induced Liver Injury for the Stratification of Tuberculosis Patients
(ALISTER) clinical study at the Royal Infirmary, Edinburgh
(ClinicalTrials.gov Identifier: NCT03211208). Participants with HIV-TB
coinfection were recruited into the Safety and Efficacy of High Dose
Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on
Efavirenz- or Dolutegravir-based Antiretroviral Therapy (SAEFRIF)
clinical trial at the Infectious Disease Institute, Kampala, Uganda
(ClinicalTrials.gov Identifier: NCT03982277).
2.1 | Healthy subjects
As a control group to test whether circulating miR-122 and K18 were
affected by active TB, latent TB or NTM infection, adults with no
medical complaints and no medication use were recruited and blood
was drawn with informed consent.
2.2 | ALISTER clinical study
Participants were recruited at the Royal Infirmary of Edinburgh. Adults
(≥16 years, ≤85 years), receiving treatment for active or latent TB, or
NTM infection were included. Patients were excluded if they did not
have the capacity to provide informed consent or were known to be
HIV positive. Full written informed consent was obtained from every
participant and the study was approved by the West of Scotland
Research Ethics Committee.
Patients were classified as having active TB either if they had cul-
ture confirmation of Mycobacterium tuberculosis and presence of
active disease, or if a clinician decided there was sufficient evidence
of active disease to start them on treatment. Latent TB patients had a
positive interferon-γ release assay and no evidence of active disease.
Patients with NTM infection had grown at least 2 cultures with non-
tuberculous mycobacterium and had clinical signs of pulmonary
disease.22,23
Active and latent TB patients were treated following World
Health Organisation guidelines.24,25 Patients with susceptible active
TB were treated with isoniazid, rifampicin, ethambutol and
pyrazinamide for an initiation phase of 2 months, followed by rifampi-
cin and isoniazid for a continuation phase of 4 months.24 Patients with
latent TB were treated with either a combination of isoniazid and
rifampicin for 3 months, or isoniazid or rifampicin alone for
6 months.25 Patients with Mycobacterium avium complex infection
were treated with the recommended regimen of rifampicin,
ethambutol and clarithromycin for 2 years.23 Dependent on the NTM
species, disease severity, resistance profile of the infection and toler-
ance of the individual, drugs were replaced or added, including isonia-
zid, moxifloxacin, azithromycin and amikacin.22,23
2.3 | SAEFRIF clinical trial
The SAEFRIF clinical trial (NCT03982277) was performed at the
Infectious Disease Institute at Makerere University, Uganda. The data
presented in this paper provide preliminary data on liver safety from
64 trial participants. A full report on predefined study end-points will
be provided on trial completion. Ethical approval for this study was
sought from Joint Clinical Research Council ethics committee, the
National Drug Authority and the Uganda National Council for Science
and Technology. All participants signed an informed consent form
prior to study enrolment.
Inclusion criteria were HIV-infected patients aged ≥18 years who
were due to initiate rifampicin-containing therapy for newly diag-
nosed active TB, and were either already taking or planning to start
efavirenz-based or dolutegravir-based antiretroviral therapy. Exclu-
sion criteria were patients who have rifampicin resistant TB, pregnant
women, women of reproductive age on dolutegravir who decline the
use of effective contraceptive, patients with liver disease, ALT > 5×
ULN or glomerular filtration rate < 50 mL/min.
The trial protocol is described by Nabisere et al.26 Patients were
randomised to 1 of 4 arms of the trial for the first 2 months of treat-
ment, either the standard (10 mg/kg) or high dose (35 mg/kg) rifampi-
cin alongside standard doses of the other first line TB drugs and either
efavirenz- or dolutegravir-based antiretroviral therapy. Baseline blood
samples (serum) were collected at baseline and weeks 2, 4, 6 and 8 of
treatment.
2.4 | Data and blood samples
For the ALISTER study and SAEFRIF trial demographic and clinical
data from the participants were recorded from medical records and
clinical trial records. Liver function test results (ALT) were recorded
from each clinic visit. Blood samples were collected at first clinic visit
and subsequent clinic visits. Once collected, blood was processed by
centrifugation and the supernatant was aliquoted and stored
at −80C.
2.5 | Quantification of miR-122
Serum samples were stored at −80C before analysis. Freeze–thaw
cycles were avoided to preserve miRNA integrity. MiR-122 was quan-
tified in samples from healthy volunteers and the ALISTER study. miR-
122 could only be measured in Edinburgh. Due to the global COVID
pandemic and the HIV-positive status of the SAEFRIF samples these
could not be shipped and miR-122 was not measured. All ALISTER
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samples were stored for a maximum of 1 year (median [interquartile
range, IQR]: 16.3 [7.6–33.3] weeks). This is less time in storage than
previously published studies, which have demonstrated miRNA stabil-
ity.27,28 MiRNA was extracted using the miRNeasy Serum/Plasma kit
(Qiagen, Venlo, Netherlands) following the manufacturer's instruc-
tions. Total RNA was extracted from 50 μL diluted in 150 μL nuclease
free water. Briefly, RNA was extracted from the serum by lysis
reagent (1000 μL) and chloroform (200 μL). After centrifugation at
12 000 × g for 15 minutes at 4C up to 600 μL of the aqueous phase
was transferred to a new tube with 900 μL absolute ethanol. RNA
was purified on a RNeasy minElute spin column and eluted in 15 μL
RNase-free water and stored at −80C. Extraction efficiency was
monitored by adding 5.6 × 108 copies of synthetic Caenorhabditis
elegans miR-39 spike-in control after the addition of lysis reagent
before the addition of chloroform and phase separation. The miScript
II Reverse Transcription kit was used to prepare cDNA according to
the manufacturer's instructions. Briefly, 2.5 μL of RNA eluate was
reverse transcribed into cDNA. The synthesised cDNA was diluted
and used for cDNA template in combination with the miScript SYBR
Green polymerase chain reaction (PCR) kit (Qiagen, Venlo, The Neth-
erlands) using the specific miScript assays (Qiagen, Venlo, The Nether-
lands). Reverse transcription (RT)-PCR was performed in duplicate on
a Light Cycler 480 (Roche, Burgess Hill, UK) using the recommended
miScript cycling parameters. In this study, miR-122 was quantified in
fM by generating a standard curve. Serial dilutions of known standard
were made using synthetic miR-122 (syn hsa-miR-122-5p, 219600,
Qiagen). The dilutions were prepared in triplicate, using the same RT
and PCR protocol as described above. The cycle threshold (Ct) values
were plotted against the logarithm of the concentration, demonstrat-
ing a clear linear relationship between Ct value and Log (conc.). The
Ct is defined as the number of PCR cycles required for the fluorescent
signal to cross the threshold (exceed background level). The resultant
regression line was used to ascertain the concentration of miR-122
present in the samples. Acceptable repeatability was demonstrated by
measuring the intra-assay variability of miR-122 duplicates29 and
expressed as concentration (fM) per MIQE guidelines30 (CV: 0.25%,
[0.11–0.49% IQR]). The intra-assay variation in miR-39 Ct values was
assessed (CV median [IQR]: 3.04 [2.50–3.64] %). Reproducibility was
determined by measuring interassay variability across plates and days
by measuring miR-122 concentrations of reference samples. A no-
enzyme control, omitting the reverse transcriptase enzyme during
reverse transcription, and no-template control omitting the cDNA in
the RT-PCR plate were also included in every run. No-enzyme and
no-template controls had Ct values of >35. Ct values <35 were reg-
arded as positive amplification signals.
2.6 | Quantification of K18
Samples were stored at −80C before analysis. K18 was quantified in
samples from healthy volunteers and patients in the ALISTER study,
with these samples stored for a maximum of just over 2 years
(113 wk; median [IQR]: 48.4 [28.7–77.8] wk) prior to analysis. The
K18 assay was established and samples were analysed by author
S.A.E.R. in Uganda. K18 was quantified in serum samples from the
SAEFRIF trial, these samples were stored for a maximum of 1 year
(median [IQR]: 19.1 [11.1–26.2] wk). K18 has been reported as stable
in serum up to 7 freeze–thaw cycles31 and for up to 2 years when fro-
zen.32 Total K18 was quantified using the Peviva M65 classic
enzyme-linked immunosorbent assay (Bioaxxes, Tewkesbury, Glos,
UK), according to the manufacturer's instructions. Samples were mea-
sured in duplicate. CV values for the dataset were (median [IQR]:
2.85% [1.33–4.97%]). Reproducibility was determined using the pro-
vided plate controls.
2.7 | Assessment of causality
DILI was predefined in this study as >3× ULN ALT in the presence of
symptoms or >5× ULN in absence of symptoms.8 The ULN for ALT
was 50 IU/L in the populations studied, as defined by local clinical
practice. The Roussel Uclaf Causality Assessment Method (RUCAM)
was used to determine formal causality between anti-TB medication
and liver injury.33 The pattern of liver injury was determined using the
R ratio, considering ALT and alkaline phosphatase activity. Further
factors considered include time to onset, course of injury, risk factors
(age and alcohol), concomitant drugs, the exclusion of nondrug causes
of injury and previous information on drug hepatotoxicity.
2.8 | Statistical analysis
Data were summarised as median (IQR) or n (%) for summary statistics
of the study participants. One-way Kruskal–Wallis ANOVA was used
to determine the difference in miR-122 and K18 between the healthy
subjects and different patient groups. Wilcoxon matched-pairs signed
rank test was used to determine the difference in miR-122 and K18
upon starting treatment. The coefficient of variation was calculated
across 3 or more samples to assess the intraindividual variability of
ALT and K18 in the HIV-TB coinfected population. Correlation of the
biomarkers was determined using Spearman's rank correlation. The
difference between miR-122 or K18 in samples grouped by ALT was
determined using a Mann–Whitney t-test. A receiver operating char-
acteristic (ROC) analysis was undertaken on all patient samples
grouped by normal ALT (≤50 IU/L) and elevated ALT (>50 IU/L). Sta-
tistical analyses were performed using Graphpad Prism (GraphPad
Software, La Jolla, California).
3 | RESULTS
A total of 207 patients were recruited into the study, along with
28 healthy volunteers; in ALISTER: active TB (n = 30), latent TB (n =
88), NTM infection (n = 25); in SAEFRIF: HIV-TB coinfection (n = 64).
The healthy volunteers had a median age of 27 years (IQR 24–30) and
64% were male. All were white British. Demographic and clinical
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Age (y) 41 (33–56) 40 (23–63) 66 (57–74) 38 (32–44)
Sex Male 20 (67%) 23 (26%) 10 (40%) 40 (62%)
Female 10 (33%) 65 (74%) 15 (60%) 24 (38%)
Ethnicity African 2 (7%) 7 (8%) 0 (0%) 64 (100%)
Arab 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Bangladeshi 1 (3%) 2 (2%) 0 (0%) 0 (0%)
Indian 7 (23%) 3 (3%) 0 (0%) 0 (0%)
Iraqi 1 (3%) 0 (0%) 0 (0%) 0 (0%)
Pakistani 5 (17%) 3 (3%) 1 (4%) 0 (0%)
South--east Asian 2 (7%) 1 (1%) 0 (0%) 0 (0%)
White 12 (40%) 66 (75%) 24 (96%) 0 (0%)
Unknown 0 (0%) 5 (6%) 0 (0%) 0 (0%)
Location of infection Pulmonary 11 (37%) - - 51 (80%)
Extrapulmonary 16 (53%) - - 9 (14%)
Both 3 (10%) - - 1 (1%)
Unknown 0 (0%) - - 3 (5%)
Culture confirmed Yes 20 (67%) - - 64 (100%)
No 10 (33%) - - 0 (0%)
Resistance None 26 (87%) - - -
Isoniazid 1 (3%) - - -
Pyrazinamide 2 (7%) - - -
Rifampicin 0 (0%) - - -
MDR 1 (3%) - - -
NTM species Mycobacterium avium complex - - 22 (88%) -
Mycobacterium abscessus - - 2 (8%) -
Mycobacterium malmoense - - 1 (4%) -
Baseline ALT (IU/L) 18 (14–35) 15 (12–21) 15 (12–22) 20 (14–30)
Treatment Isoniazid, rifampicin - 43 (48%) - -
Isoniazid - 26 (30%) - -
Rifampicin - 18 (20%) - -
Moxifloxacin - 1 (1%) - -
Rifampicin, azithromycin - 1 (4%) -
Rifampicin, clarithromycin - - 3 (12%) -
Rifampicin, clarithromycin, amikacin - - 1 (4%) -
Rifampicin, ethambutol - - 1 (4%) -
Rifampicin, ethambutol, amikacin - - 1 (4%) -
Rifampicin, ethambutol, clarithromycin - - 15 (60%) -
Rifampicin, ethambutol, moxifloxacin - - 1 (4%) -
Rifabutin, clarithromycin, moxifloxacin - - 1 (4%) -




- - - 64 (100%)
Initiation phase Isoniazid, rifampicin, pyrazinamide,
ethambutol
22 (73%) - - -
(Continues)
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characteristics for patients within ALISTER and SAEFRIF are
presented in Table 1. There was no significant difference in miR-122
(P = .09) between the groups. There was a statistically significant but
clinically minor difference in K18 between groups (P = .03; Table 2,
Figure 1). Serial samples were collected in 65 patients in the ALISTER
study (Figure 2). The time patients had spent on treatment was
median (IQR): active TB 3.0 (2.4–6.9); latent TB 3.9 (2.4–12.2); NTM
infection 4.0 (2.2–6.9) weeks. Commencing treatment was associated
with a statistically significant, clinically insignificant increase in ALT
(median [IQR]: baseline 15 [12–24]; on treatment 17 [13–27] IU/L;
P = .03) and miR-122 (median [IQR]: baseline 3.12 [1.20–5.63]; on
















1 (3%) - - -
Isoniazid, rifabutin, pyrazinamide,
ethambutol
1 (3%) - - -
Isoniazid, rifampicin, ethambutol,
moxifloxacin
3 (10%) - - -
Rifampicin, ethambutol, moxifloxacin 1 (3%) - - -
Bedaquiline, clofazimine, cycloserine 1 (3%) - - -
Continuation phase Isoniazid, rifampicin 20 (67%) - - -
Isoniazid, rifampicin, moxifloxacin 2 (7%) - - -
Isoniazid, rifampicin, ethambutol 2 (7%) - - -
Isoniazid, Rifabutin, moxifloxacin 1 (3%) - - -
Isoniazid, ethambutol, moxifloxacin 1 (3%) - - -
Isoniazid, rifampicin, pyrazinamide,
ethambutol
1 (3%) - - -
Rifampicin, ethambutol, moxifloxacin 2 (7%) - - -
Bedaquiline, clofazimine, cycloserine 1 (3%) - - -
ALT, alanine transaminase; HIV, human immunodeficiency virus; MiR, microRNA; NTM, nontuberculous mycobacterial; TB, tuberculosis
TABLE 2 Circulating ALT, miR-122 and K18 in individuals with normal ALT (<50 IU/L) in healthy volunteers and first samples taken upon











ALT (IU/L) Median 18 22 16 16 18
[IQR] [12–22] [14–27] [12–23] [13–25] [14–27]
Coefficient of
variation (%)
44.0 40.7 48.4 54.3 50.3
MiR-122 (fM) Median 2.88 4.14 2.92 1.57 -
[IQR] [1.75–3.96] [1.34–7.56] [1.46–4.54] [0.91–3.72]
Coefficient of
variation (%)
65.8 183.4 120.6 168.5 -
K18 (U/L) Median 210 145 152 163 172
[IQR] [134–259] [92–220] [105–215] [138–263] [132–276]
Coefficient of
variation (%)
45.9 62.2 207.8 69.2 79.4
ALT, alanine transaminase; HIV, human immunodeficiency virus; IQR, interquartile range; MiR, microRNA; NTM, nontuberculous mycobacteria; TB,
tuberculosis.
6 RUPPRECHTER ET AL.
K18, which did not reach statistical significance (median [IQR]: base-
line 150 [103–224]; on treatment 167 [110–246] U/L; P = .4). Serial
samples were also collected in 50 SAEFRIF patients (Figure 3). In the
SAEFRIF patients, starting treatment did not lead to a significant
change in ALT (median [IQR]: week 0: 22 [14–31]; week 2:
24 [14–32] IU/L; P = .62) or K18 (median [IQR]: week 0:
204 [130–344]; week 2: 169 [117–262] U/L; P = .3).
When all samples from all time points were included, there was a
significant correlation between ALT and miR-122 (n = 251, Spearman
rank r = 0.52, 95%CI = 0.42–0.61, P < .0001; Figure 4A). There was a
significant, but less tight, correlation between ALT and K18 (n = 491,
Spearman rank r = 0.42, 95% CI = 0.34–0.49, P < .0001; Figure 4B).
miR-122 correlated with K18 (n = 252, Spearman rank r = 0.32, 95%
CI = 0.20–0.43, P < .0001; Figure 4C).
MiR-122 was increased 8.0-fold in samples with elevated ALT
(>50 IU/L) compared to samples with normal ALT (predefined as
≤50 IU/L; median [IQR]: elevated ALT 23.9 [11.5–60.4]; normal ALT
3.00 [1.31–4.82] fM; P < .0001; Figure 5A). K18 was increased
2.3-fold in those samples with elevated ALT (>50 IU/L) compared to
samples with normal ALT (≤50 IU/L; median [IQR]: elevated ALT
395 [217–683]; normal ALT 170 [120–250] U/L; P < .0001;
Figure 5B). ROC analysis was performed on these grouped samples
(Figure 5C,D). MiR-122 identified elevated ALT (>50 IU/L) with high
accuracy (ROC-AUC = 0.93, 95% CI = 0.88–0.98, P < .001). K18 iden-
tified elevated ALT (>50 IU/L) with lower accuracy (ROC-AUC = 0.80,
95% CI = 0.72–0.87, P < .0001). The sensitivity and specificity of miR-
122 and K18 was unchanged when only samples from patients on
treatment were included in the analysis (miR-122: ROC-AUC = 0.93,
95%CI = 0.87 to 0.99, P < .0001. K18: ROC-AUC = 0.78, 95%
CI = 0.68 to 0.87, P < .0001; Figure S1).
The interindividual variability in miR-122, K18 and ALT was com-
pared in the different patient groups (Table 2). Interindividual variabil-
ity was higher for both miR-122 and K18 than ALT. Sequential
samples from the SAEFRIF trial (patients with normal ALT (<50 IU/L)
and 3 or more samples collected) were analysed to determine the
intraindividual variability over time (CV median [IQR]: ALT 23.9
[16.6–36.1] %; K18 35.4 [24.9–41.9] %; P = .02). Intraindividual vari-
ability was higher for K18 than ALT.
In this study there were 2 cases of DILI (as predefined in study
protocols), both cases were for patients receiving isoniazid alone for
the treatment of latent TB within the ALISTER study. The first case
was of a 51-year-old white British male patient, who experienced
peak ALT activity of 431 IU/L, (Figures 6A,E). Before starting treat-
ment, he had normal ALT (18 IU/L), miR-122 was 4 fM and his K18
F IGURE 1 Circulating concentration
of A, alanine transaminase (ALT; IU/l),
B, microRNA (miR)-122 (fM) and C, K18
(U/L). Data are the first collected samples
from the ALISTER study or SAEFRIF trial.
Participants include healthy volunteers
(n = 28), active tuberculosis (TB; n = 26),
latent TB (n = 87), nontuberculous
mycobacteria (NTM) infection (n = 25)
and human immunodeficiency virus
(HIV)–TB coinfection (n = 59). Data are
presented as dot plots. Line shows
median and bars show interquartile
range. The significance of differences
between groups were determined
by 1-way Kruskal–Wallis ANOVA
(ALT P = .2; miR-122 P = .09;
K18 P = .03)
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was 58 U/L. Three months into treatment, his ALT activity increased
to 431 IU/L, miR-122 rose to 60 fM and K18 rose to 1248 U/L. Drug
treatment was halted and ALT returned to within normal limits
18 weeks later. Formal causality between isoniazid and liver injury
was determined using the RUCAM scale and was determined as prob-
able (RUCAM scale = 6).
The second case was of a 71-year-old white British female
patient, (Figures 6B,D,F). At baseline her ALT activity was 28 IU/L,
miR-122 was 17 fM and K18 was 219 U/L. Two weeks into treat-
ment, her ALT activity had not increased (25 IU/L) but K18 and
miR-122 had risen (307 U/L and 63 fM, respectively). DILI was
present 5 weeks into treatment with the presence of a drug rash
and elevated ALT at 194 IU/L. At this time, K18 activity had risen
to 3490 U/L and miR-122 concentration had increased further to
336 fM. Drug treatment was halted, and the patient was dis-
charged and lost to further follow up. RUCAM causality
F IGURE 2 Circulating concentration
of A, alanine transaminase (ALT; IU/L),
B, microRNA (miR)-122 (fM) and C, K18
(U/L) in sequential samples in patients
within the ALISTER study, (active
tuberculosis, n = 9; latent tuberculosis,
n = 46; nontuberculous mycobacteria,
n = 10) Data shown as dot plots. Black
dots show patients with normal ALT
activity at baseline and on treatment;
blue dots show patients with ALT activity
>50 U/L at baseline which decreased on
treatment; red dots show patients whose
ALT increased above 50 U/L with
treatment. Dotted line on (A)
ALT = 50 IU/L. The significance of
differences between baseline and on
treatment concentrations of biomarkers
was determined by Wilcoxon signed rank
test (ALT P = .03; miR-122 P = .01;
K18 P = .4)
F IGURE 3 Circulating concentration
of A, alanine transaminase (ALT; IU/L)
and B, K18 (U/L) for sequential samples
in patients within the SAEFRIF trial. Black
dots show patients with normal ALT
throughout treatment, red points show
patients whose ALT rises >50 IU/L during
treatment, blue points show patients
whose ALT falls from >50 IU/L upon
starting treatment. Dotted line on (A)
ALT = 50 IU/L
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F IGURE 4 Correlation of
A, microRNA (miR)-122 (fM) vs. alanine
transaminase (ALT; IU/L), B, K18 (U/L) vs.
ALT (IU/L) and C, miR-122 (fM) vs. K18
(U/L). Patient samples (healthy
volunteers, n = 28; active tuberculosis
[TB], n = 44; latent TB, n = 142;
nontuberculous mycobacteria [NTM]
infection, n = 39; human
immunodeficiency virus–tuberculosis
[HIV-TB] coinfection, n = 241). Statistical
analysis of the significance of the
correlation calculated using Spearman's
rank correlation coefficient (miR-122 vs.
ALT: n = 251, Spearman rank R = .52,
95% CI 0.42–0.61, P < .0001; K18 vs.
ALT: n = 491, Spearman rank R = .42,
95% CI 0.34–0.49, P < .0001; miR-122 vs.
K18: n = 252, Spearman rank R = .32,
95% CI 0.20–0.43, P < .0001)
F IGURE 5 Comparison of samples
grouped by normal alanine transaminase
(ALT; ≤50 IU/L) and elevated ALT
(>50 IU/L). A, MicroRNA (miR)-122
concentration (fM) and B, K18 (U/L).
Patient samples (healthy volunteers,
n = 28; active tuberculosis [TB,] n = 44;
latent TB, n = 142; nontuberculous
mycobacteria infection, n = 39; HIV-TB
coinfection, n = 241). Statistical analysis
of the significance of the difference
between the groups calculated with
the Mann–Whitney t-test (miR-122
P < .0001; K18 P < .0001). Receiver
operator characteristic (ROC) analysis of
samples grouped by normal ALT
(≤50 IU/L) and elevated ALT (>50 IU/L),
C, miR-122 and D, K18. MiR-122 (ROC-
area under the curve [AUC] = 0.93, 95%
CI = 0.88–0.98, P < .001). K18 (ROC-
AUC = 0.80, 95% CI = 0.72–0.87,
P < .0001)
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assessment indicated that isoniazid was the probable cause of liver
injury (RUCAM scale = 7).
4 | DISCUSSION
The utility of miR-122 and K18 as exploratoryDILI biomarkers has been
demonstrated by several multicentre studies and this has resulted in
Food and Drug Administration support for continued development to
full qualification.21 However, the properties of these biomarkers have
not been robustly studied in patients with TB in Africa.
Given the potential involvement of the liver in TB infection, it
was important to determine if circulating concentrations of miR-122
and K18 differed from healthy individuals in the presence of infection,
including active, latent and NTM infection and HIV-TB coinfection.
For example, if either biomarker was elevated by mycobacterial infec-
tion per se then it would be de-prioritised as a biomarker in this impor-
tant context of use. In this study, we have demonstrated that
circulating miR-122 and K18 in healthy volunteers and patients with
active TB, latent TB and NTM infection are not substantially different.
This suggests that the presence of mycobacterial infection does not
affect circulating miR-122 and K18. Furthermore, circulating K18 in
HIV-TB coinfected African patients was similar to the other groups,
which were predominantly Caucasian. This suggests that the healthy
reference interval for K18 in an African and Caucasian population is
likely to be similar. In addition, we have demonstrated that, in the
absence of DILI, neither miR-122 nor K18 change substantially upon
commencing treatment. Both miR-122 and K18 correlate with ALT,
indicating these biomarkers may have diagnostic utility. In this pilot
study, miR-122 distinguished those patients with an elevated ALT
F IGURE 6 Circulating concentration of (A, B)
alanine transaminase (ALT; IU/L), (C, D)
microRNA (miR)-122 (fM) and (E, F) K18 (U/L)
over the course of treatment (weeks) for 2 cases
who developed DILI as predefined as >3× upper
limit of normal ALT in the presence of symptoms
or >5× upper limit of normal in absence of
symptoms.8 Case 1 (A, C, E); Case 2 (B, D, F)
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with greater sensitivity and specificity than K18 but this should be
interpreted with caution as there were only 2 cases of DILI as
predefined in our study protocol. In these DILI cases, the elevations in
ALT temporarily correlated with a rise in both miR-122 and K18. In
addition, in 1 of these patients, miR-122 and K18 rose before ALT,
indicating a potential for these novel biomarkers to predict the devel-
opment of DILI earlier than ALT. The results of this study provide ini-
tial evidence for the potential use of both miR-122 and K18 as
biomarkers of TB medicine associated DILI.
Further work should focus on determining the diagnostic value of
the biomarkers, whether they correlate with rises in ALT and so can
diagnose DILI within this population. A clear definition of the dynamic
range, sensitivity and specificity of miR-122 and K18 within this popu-
lation is needed before they can be used as a biomarker of DILI. Fur-
thermore, given that evidence suggests miR-122 and K18 both rise
earlier than ALT in paracetamol DILI, it is important to determine if
they have the same predictive value in patients with mycobacterial
infections. This predictive ability of these novel biomarkers may
enable early identification of patients at risk of DILI, leading to pre-
vention of liver injury through halting or altering treatment regimens
before significant liver injury develops. Specifically, the biomarkers
could be a useful early indicator of the development of DILI in
patients being reintroduced to essential anti-TB medications, a group
at elevated risk of DILI recurrence.
Our study had a limited number of cases of anti-TB DILI. His-
torical data suggested approximately 2–5% of patients receiving
anti-TB treatment in the UK will develop DILI. However, within the
ALISTER study only 2 patients developed DILI, 1.4% of the patients
recruited. Larger multicentre studies are required to recruit enough
patients to determine the diagnostic power of miR-122 and K18 in
anti-TB DILI. The majority of values for circulating miR-122 concen-
trations in the patient groups fell within the published upper limit of
the healthy reference interval of 45 fM generated from the SAFE-T
dataset.34 However, there were 2 patients with miR-122 increased
above this healthy reference interval (miR-122 = 77 and 77 fM)
when ALT was still normal (ALT = 25 and 26 IU/L). This may reflect
a limitation of miR-122, namely that it has been reported to have
relatively high variability.34 In our study, the variability of the novel
biomarkers was higher than ALT, with miR-122 having higher inter-
subject variability than K18. Although the previously published
healthy reference interval provides a valuable comparison, the circu-
lating concentration of miR-122 in healthy volunteers in this study
fell between 0.21 and 8.75 fM, considerably lower than the publi-
shed ULN of 45 fM, which was generated from the SAFE-T
dataset.34 This healthy reference interval was developed using a
larger sample size than that included in this study. However, it was
determined using different quantification and normalisation
methods, therefore a direct comparison is challenging. There were
2 patients who had substantially elevated K18 in the absence of
elevated ALT. Firstly, in ALISTER (K18 = 4207 U/L, ALT = 43 IU/L).
Secondly, in the SAEFRIF trial, where a patient had K18 ranged
from 10 000–20 000 U/L, but not substantially elevated ALT
(22–52 IU/L). The reason for these 2 outliners is unknown and
requires further study with larger patient numbers. Another limita-
tion of our study is that miR-122 was only measured in the
ALISTER cohort, whereas K18 was measured in both ALISTER and
SAEFRIF cohorts. This limitation was due miR-122 only being mea-
sured in Edinburgh. The global COVID pandemic and the HIV-
positive status of the SAEFRIF samples meant these could not be
transferred out of Uganda. Given the possible superior sensitivity/
specificity of miR-122 over K18 which is suggested by this pilot
study it will be important for future studies to measure miR-122 in
the African setting. Finally, this study did not include patients rec-
ruited in Asia, a region with high TB prevalence. This group should
be included in future studies.
In summary, the presence of mycobacterial infection does not
alter miR-122 or K18 concentrations in the absence of DILI. African
HIV-TB coinfected patients had similar K18 concentrations to healthy
volunteers and Caucasian TB patients. Patients who experienced ele-
vations in ALT also demonstrated rises in both miR-122 and K18 indi-
cating the diagnostic potential of these biomarkers. Future trials of
miR-122 and K18 as biomarkers of anti-TB DILI could be performed
using the data presented in this paper to inform the study design.
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